
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Dr Stephen Oh reviews the use of pacritinib in patients with myelofibrosis and the impact on anemia. Funding supported by CTI Biopharma. Content independently developed by OncLive.
Funding supported by CTI Biopharma. Content independently developed by OncLive.






